References
- Chen SN, Zhang HP, Wang LQ, et al. Diterpenoids from the flowers of Rhododendron molle. J Nat Prod 2004;67:1903–6
- Terai T, Sato M, Narama I, et al. Transformation of grayanotoxin III to 10-epi-grayanotoxin III. Its X-ray crystallographic analysis and acute toxicity in mice. Chem Pharm Bull (Tokyo) 1996;44:1245–7
- Koca I, Koca AF. Poisoning by mad honey: a brief review. Food Chem Toxicol 2007;45:1315–18
- Burke JW, Doskotch RW. High field 1H- and 13C-nmr assignments of grayanotoxins I, IV, and XIV isolated from Kalmia angustifolia. J Nat Prod 1990;53:131–7
- Akera T, Ku DD, Frank M, et al. Effects of grayanotoxin I on cardiac Na + K + -adenosine triphosphatase activity, transmembrane potential and myocardial contractile force. J Pharmacol Exp Ther 1976;199:247–54
- Sahin H, Aliyazicioglu R, Yildiz O, et al. Honey, pollen, and propolis extracts show potent inhibitory activity against the zinc metalloenzyme carbonic anhydrase. J Enzyme Inhib Med Chem 2011;26:440–4
- Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov 2008;7:168–81
- Supuran CT. Carbonic anhydrase inhibitors. Bioorg Med Chem Lett 2010;20:3467–74
- Supuran CT. Bacterial carbonic anhydrases as drug targets: toward novel antibiotics? Front. Pharmacol 2011;2:1--6
- Pastorekova S, Parkkila S, Pastorek J, et al. Carbonic anhydrases: Current state of the art, therapeutic applications and future prospects. J Enzyme Inhib Med Chem 2004;19:199–229
- Neri D, Supuran CT. Interfering with pH regulation in tumours as a therapeutic strategy. Nature Reviews Drug Discovery 2011;10:767–77
- Supuran CT, Scozzafava A, Casini A. Carbonic anhydrase inhibitors. Med Res Rev 2003;23:146–89
- Svastova E, Hulikova A, Rafajova M, et al. Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH. Febs Lett 2004;577:439–45
- Ebbesen P, Pettersen EO, Gorr TA, et al. Taking advantage of tumor cell adaptations to hypoxia for developing new tumor markers and treatment strategies. J Enzyme Inhib Med Chem 2009;24:1–39
- Wykoff CC, Beasley NJ, Watson PH. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 2000;60:7075–83
- Lou Y, McDonald PC, Oloumi A, et al. Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors. Cancer Res 2011;71:3364–76
- Pacchiano F, Carta F, McDonald PC, et al. Ureido-substituted benzenesulfonamides potently inhibit carbonic anhydrase IX and show antimetastatic activity in a model of breast cancer metastasis. J Med Chem 2011;54:1896–902
- Supuran CT. Diuretics: From classical carbonic anhydrase inhibitors to novel applications of the sulfonamides. Curr Pharm Design 2008;14:641–8
- De Simone G, Di Fiore A, Supuran CT. Are carbonic anhydrase inhibitors suitable for obtaining antiobesity drugs? Curr Pharm Design 2008;14:655–60
- Maresca A, Temperini C, Vu H, et al. Non-zinc mediated inhibition of carbonic anhydrases: coumarins are a new class of suicide inhibitors. J Am Chem Soc 2009;131:3057–62
- Carta F, Temperini C, Innocenti A, et al. Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule. J Med Chem 2010;53:5511–22
- Innocenti A, Vullo D, Scozzafava A, et al. Carbonic anhydrase inhibitors: interactions of phenols with the 12 catalytically active mammalian isoforms (CA I-XIV). Bioorg Med Chem Lett 2008;18:1583–7
- Davis RA, Hofmann A, Osman A, et al. Natural product-based phenols as novel probes for mycobacterial and fungal carbonic anhydrases. J Med Chem 2011;54:1682–92
- Khalifah RG. The carbon dioxide hydration activity of carbonic anhydrase. I. Stop-flow kinetic studies on the native human isoenzymes B and C. The Journal of Biological Chemistry 1971;246:2561–73
- Alterio V, Di Fiore A, D’Ambrosio K, et al. X-ray crystallography of CA inhibitors and its importance in drug design. In: Supuran CT, Winum JY, eds. Drug design of zinc-enzyme inhibitors: functional, structural, and disease applications. Hoboken (NJ): Wiley; 2009:73–138
- Alterio V, Di Fiore A, D’Ambrosio K, et al. Crystal structure of the catalytic domain of the tumor-associated human carbonic anhydrase IX. Proc Natl Acad Sci U S A 2009;106:16233–8
- Casini A, Antel J, Abbate F, et al. Carbonic anhydrase inhibitors: SAR and X-ray crystallographic study for the interaction of sugar sulfamates/sulfamides with isozymes I, II and IV. Bioorg Med Chem Lett 2003;13:841–5
- Avvaru BS, Wagner JM, Maresca A, et al. Carbonic anhydrase inhibitors. The X-ray crystal structure of human isoform II in adduct with an adamantyl analogue of acetazolamide resides in a less utilized binding pocket than most hydrophobic inhibitors. Bioorg Med Chem Lett 2010;20:4376–81
- Wagner J, Avvaru BS, Robbins AH, et al. Coumarinyl-substituted sulfonamides strongly inhibit several human carbonic anhydrase isoforms: solution and crystallographic investigations. Bioorg Med Chem 2010;18:4873–8
- Pacchiano F, Aggarwal M, Avvaru BS, et al. Selective hydrophobic pocket binding observed within the carbonic anhydrase II active site accommodate different 4-substituted-ureido-benzenesulfonamides and correlate to inhibitor potency. Chem Commun 2010;46:8371–3
- Temperini C, Innocenti A, Scozzafava A, et al. The coumarin-binding site in carbonic anhydrase accommodates structurally diverse inhibitors: the antiepileptic lacosamide as an example and lead molecule for novel classes of carbonic anhydrase inhibitors. J Med Chem 2010;53:850–4
- Durdagi S, Senturk M, Ekinci D, et al. Kinetic and docking studies of phenol-based inhibitors of carbonic anhydrase isoforms I, II, IX and XII: evidence of a new binding mode within the enzyme active site. Bioorg Med Chem 2011;19:1381–9
- Balaydin H, Turker H, Durdagi S, et al. Inhibition of human carbonic anhydrase isozymes I, II, and VI with a series of bisphenol, methoxy and bromophenol compounds. J Enzy Inh Med Chem 2012;27:467–75
- Innocenti A, Durdagi S, Doostdar N, et al. Nanoscale enzyme inhibitors: fullerenes inhibit carbonic anhydrase by occluding the active site entrance. Bioorg Med Chem 2010;18: 2822–8
- Talaz O, Cavdar H, Durdagi S, et al. Synthesis of 1,4-bis(indolin-1-ylmethyl)benzene derivatives and their structure-activity relationships for the interaction of human carbonic anhydrase isoforms I and II. Bioorg Med Chem 2013;21:1477–82
- Friesner RA, Murphy RB, Repasky Frye LL, et al. Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J Med Chem 2006;49:6177–96
- Subbotina J, Yarov-Yarovoy V, Lees-Miller J, et al. Structural refinement of the hERG1 pore and voltage-sensing domains with ROSETTA-membrane de-novo modeling and molecular-dynamics simulations. Proteins: Struct Funct Bioinform 2010;78:2922–34
- Cakmak R, Durdagi S, Ekinci D, et al. Design, synthesis and biological evaluation of novel nitroaromatic compounds as potent glutathione reductase inhibitors. Bioorg Med Chem Lett 2011;21:5398–402
- Politi A, Durdagi S, Moutevelis-Minakakis P, et al. Development of accurate binding affinity predictions of novel renin inhibitors through molecular docking studies. J Mol Graph Model 2010; 29:425–35
- Durdagi S, Zhao C, Cuervo JE, Noskov SY. Atomistic models for free energy evaluation of drug binding to membrane proteins. Curr Med Chem 2011;18:2601–11
- Mavromoustakos T, Durdagi S, Koukoulitsa C, et al. Strategies in the rational drug design. Curr Med Chem 2011;18:2517–30
- Durdagi S, Subbotina J, Lees-Miller J, et al. Insights into molecular mechanism of herg1 channel activation and blockade by drugs. Curr Med Chem 17: 3514–32
- Temperini C, Scozzafava A, Supuran CT. Carbonic anhydrase activators: the first X-ray crystallographic study of an adduct of isoform I. Bioorg Med Chem Lett 2006;16:5152–56
- Milne RI, Abbott RJ. Origin and evolution of invasive naturalized material of Rhododendron ponticum L. in the British Isles. Mol Ecol 2000;9:541–56
- Food and Agriculture Organization of the United Nations. Data available at: http://faostat.fao.org/site/339/default.aspx [last accessed 22 Jul 2013]